Ozempic maker’s stock surges. A trial of a new Novo Nordisk drug shows promise.
Novo Nordisk shares jumped on Friday as the Danish drugmaker said an experimental drug was able to reduce weight by as much ...
Novo Nordisk stock pops on Phase 1 data for new weight loss drug amycretin
Amycretin could give Novo a buzzy product in an newly competitive obesity market. It works similarly to existing GLP-1 ...
HealthLeaders Media22m
Novo Nordisk jumps on experimental weight-loss drug trial results
Novo Nordisk on Friday reported strong early-stage results for its once-a-week obesity drug. Before the open, Novo Nordisk stock jumped while Eli Lilly fell. In the phase 1b/2a clinical trial, obese ...
5 Things to Know Before the Stock Market Opens
U.S. stock futures are pointing lower after indexes neared or set all-time highs yesterday; Novo Nordisk stock is jumping in ...
STAT2m
Neomorph, AbbVie strike $1.64 billion deal
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hosted on MSN55m
Novo Nordisk Stock Eyes Best Day In 17 Months On New Obesity Drug Trial Data: Retail Breathes Easy
Shares of Novo Nordisk surged over 13% in premarket trading Friday, driven by promising topline results from a early-stage ...